Ftse Mib
38.592,81
-0,48%
DAX
23.008,94
-1,87%
S&P 500
5.770,20
0,55%
NASDAQ
18.196,22
0,70%
Bitcoin
86.210,67
0,07%
Pepperstone
Advertisement
Registration Strip Icon for default Registrati gratuitamente per ottenere quotazioni in tempo reale, grafici interattivi, flusso di opzioni in tempo reale e altro ancora.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ argenx SE (ARGX) argenx SE (ARGX) Notizie

argenx SE

ARGX
594,21
-18,97 (-3,09%)
08 Mar 2025 - Chiuso
Dati in Delay di 15 minuti
Borsa: NASDAQ
Tipo: Ricevuta di Deposito
Valuta: USD

Ultime notizie

Data Ora Fonte Titolo
07/3/202512:05EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
07/3/202507:00GLOBEargenx Highlights FcRn Leadership with Long-term Data and..
27/2/202512:34EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
27/2/202507:00GLOBEargenx Reports Full Year 2024 Financial Results and Provides..
25/2/202507:00GLOBEargenx to Present at TD Cowen 45th Annual Healthcare..
20/2/202507:00GLOBEargenx to Report Full Year 2024 Financial Results and Fourth..
12/2/202515:16EDGAR2Form SCHEDULE 13G/A - Statement of Beneficial Ownership by..
13/1/202507:00GLOBEargenx Highlights 2025 Strategic Priorities
06/1/202507:00GLOBEargenx to Present at 43rd Annual J.P. Morgan Healthcare..
27/12/202412:05EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
27/12/202407:00GLOBEargenx Announces Approval of VYVDURA (efgartigimod alfa and..
26/11/202407:00GLOBEargenx to Present at Upcoming Investor Conferences
20/11/202412:35EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
20/11/202407:00GLOBEargenx Advances Clinical Development of Efgartigimod SC in..
12/11/202412:35EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
11/11/202413:30BWZai Lab and argenx Announce Approval of VYVGART Hytrulo for..
05/11/202407:00GLOBEargenx to Participate at Upcoming Investor Conferences
31/10/202413:15EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
31/10/202407:00GLOBEargenx Reports Third Quarter 2024 Financial Results and..
24/10/202407:00GLOBEargenx to Report Third Quarter 2024 Financial Results and..
15/10/202414:14EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
15/10/202407:00GLOBEargenx Highlights Data Showing Patient Impact Across..
19/9/202412:06EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
19/9/202407:00GLOBEargenx Announces Publication in The Lancet Neurology of..
28/8/202407:00GLOBEargenx to Present at Upcoming Investor Conferences
25/7/202412:01EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
25/7/202407:00GLOBEargenx Reports Half Year 2024 Financial Results and Provides..
18/7/202407:00GLOBEargenx to Report Half Year 2024 Financial Results and Second..
16/7/202423:22EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
16/7/202422:03EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
16/7/202406:30GLOBEargenx and Zai Lab Announce Approval of Efgartigimod Alfa..
16/7/202406:15BWZai Lab and argenx Announce Approval of Efgartigimod Alfa..
25/6/202422:30GLOBEargenx Highlights Breadth of Autoimmune Pipeline with New..
21/6/202422:50GLOBEargenx Announces FDA Approval of VYVGART Hytrulo for Chronic..
17/6/202412:05EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
17/6/202407:00GLOBEargenx to unveil its ‘Vision 2030: Taking Breakthrough..
04/6/202407:00GLOBEargenx to Present at Goldman Sachs 45th Annual Global..
09/5/202413:06EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
09/5/202407:00GLOBEargenx Reports First Quarter 2024 Financial Results and..
08/5/202412:15EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
07/5/202423:30GLOBEargenx announces results of Annual General Meeting of..
07/5/202407:00GLOBEargenx to Present at BofA Securities 2024 Health Care..
02/5/202407:00GLOBEargenx to Report First Quarter 2024 Financial Results and..
16/4/202407:00GLOBEargenx Data Highlight Evidence that VYVGART and VYVGART..
27/3/202407:00GLOBEargenx Advances Clinical Development of Efgartigimod in..
26/3/202421:00GLOBEargenx Announces Annual General Meeting of Shareholders on..
26/3/202407:00GLOBEargenx Announces Approval of VYVGART (efgartigimod alfa) in..
Apertura: 611,505 Min: 592,70 Max: 612,40
Chiusura: 613,18

La tua Cronologia

NASDAQ
ARGX
argenx
USOTC
AEXE
Aim Exploration (CE)
Delayed Upgrade Clock

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network

Rimuovi gli annunci

Iscriviti per un'esperienza senza pubblicità

Nessuna pubblicità

Prova adesso

Conserva gli annunci